Technology evaluation: ISIS-2503, Isis Pharmaceuticals.

Published

Journal Article

ISIS-2503, a 20-mer antisense oligonucleotide that inhibits Ha-Ras expression, is being developed by Isis Pharmaceuticals Inc as a potential treatmentfor cancer, particularly tumors that commonly have abnormalities of Ras function. It is in phase II trials. According to an April 2001 report by Bear Stearns & Co, Elan Corp plc had an unspecified collaboration with Isis for the development of ISIS-2503 [419357], but Isis later clarified that there was no agreement between the two companies and that ISIS-2503 had merely been used for the 'OraSense' joint venture that explores the use of antisense oligonucleotidesfor oral administration [419673].

Full Text

Duke Authors

Cited Authors

  • Morse, MA

Published Date

  • December 2001

Published In

Volume / Issue

  • 3 / 6

Start / End Page

  • 589 - 594

PubMed ID

  • 11804274

Pubmed Central ID

  • 11804274

Electronic International Standard Serial Number (EISSN)

  • 2040-3445

International Standard Serial Number (ISSN)

  • 1464-8431

Language

  • eng